The markets continue to trade at or near all-time highs, with companies in just about every sector (even some in the beleaguered retail and much maligned oil and gas industries) trading at record valuations.
With stock markets flourishing, it’s no surprise that there has been a recent uptick in companies seeking to go public and raise money.
A whopping seven companies are set to price or have priced offerings the week of Sept. 18, including Alibaba Group Holding Ltd. (BABA) -backed logistics company Best Inc. (BSTI) ; Argentine travel website Despegar.com Corp. (DESP) , backed by Tiger Global Management LLC and Expedia Inc. (EXPE) ; and Zai Lab Ltd. (ZLAB) a Shanghai biotech developing products for oncology, autoimmune and infectious diseases. Best, Despegar.com and Zai Labs all popped in their first day of trading Wednesday, Sept. 20. IPO investment adviser Renaissance Capital LLC estimated the seven listings would raise a total of about $1.6 billion, but Oasis Midstream Partners LP (OMP) subsequently priced its offering below the expected range.
Luckily for investors, the raft of IPOs means there will be new companies where you can get in on the ground floor. And the choices are aplenty, with companies including BP plc (BP) looking to spin out assets and make a chunk of the equity available to the public. Meanwhile, bigwig private equity and venture capital investors also are looking to exit companies and in turn give the public some skin.
But before you go throwing your money at these rookie floats solely based on hype — I think we can all recall the pain some investors felt when eyeing Snap Inc. (SNAP) and Blue Apron Holdings Inc. (APRN) in their initial trading days — it’s important to know a few things. Why is the company going public, who owns it, how much will you be able to afford of the new stock, and what risks and pitfalls stand to derail an IPO or take a stock down once it begins trading.
- An Alibaba Trade as Best Makes Its Debut
But as we look ahead to the coming weeks, there will be even more companies hitting the markets to raise cash. Here’s a look at some of those readying to hit the public markets and some that may be a little further off that you should have on your radar.
Roku Streams for Success
Streaming television provider Roku Inc. likely will see its shares hit the market on Sept. 27. Rokuplans to offer about 9 million shares at a range of $12 to $14 a piece, meaning at the midpoint the company would raise about $117 million. Shareholders Menlo Ventures and Sky Ventures Ltd. are selling an addition 6 million and 668,000 shares, respectively, and the underwriters, which include Morgan Stanley, Citigroup, Allen & Co. LLC and RBC Capital Markets. have the right to purchase an additional 2.35 million shares.
The Los Gatos, Calif., company on Sept. 1 filed a Form S-1 with the Securities and Exchange Commission for an initial public offering. Roku’s Class A shares would trade as ROKU on Nasdaq.
In July, The Wall Street Journal reported that Roku was planning an IPO before the end of the year, seeking a $1 billion valuation.
The filing is the latest evidence that the tech IPO market is — in spite of some high-profiledisappointments — perking up following a big 2017 Nasdaq rally and healthy debuts for a slew of internet services and enterprise tech firms. Roku’s filing comes as “Angry Birds” developer Rovio Entertainment Ltd. pursues a Helsinki listing while reportedly aiming for a $2 billion valuation.
Roku’s revenue rose 25% in 2016, and 23% during the first half of 2017 to $199.7 million. Hardware sales, though, actually fell 2% during the latter period to $117.3 million. Revenue growth stemmed entirely from a 91% increase in Roku’s higher-margin platform revenue. That business, which covers ad sales, software licensing, branded channel buttons on Roku remotes and revenue cuts on subscriptions and on-demand content purchased on Roku devices, increased to $82.4 million.
The boost there helped Roku’s net loss drop by $9 million to $24.2 million in spite of an 18% increase in operating expenses to $97.7 million. The company recorded just a 12% GAAP gross margin on hardware revenue but a 76% margin on platform revenue. That bodes well for Roku’s ability to turn profitable over the next year or two, provided it can keep platform revenue growing quickly.
NuCana Looks to Raise Some Cash
Brought to you in part by the same venture Capital firm that brought you ZS Pharma Inc., NuCana plc, like many biotechs looking to raise capital, has yet to come up with a commercializable product, let alone turn a profit, so beware — these things can turn in a second.
Here’s what we know:
NuCana is based in Edinburgh, Scotland, and has three drugs in its pipeline that look to address chemotherapy for resistant tumors. Its most advanced product candidate, Acelarin, is currently under evaluation in four clinical trials.
The company, which has backing from Sofinnova Venture Partners and a partnership with Cardiff University in Cardiff, Wales, plans to raise about $100 million by offering 6.7 million shares at $14 to $16. At the midpoint of the proposed range, NuCana would command a market value of $463 million.
NuCana, founded in 2008, plans to list on Nasdaq under the symbol NCNA. Citigroup and notable healthcare experts Jefferies LLC and Cowen and Co. LLC are the joint bookrunners on the deal. It is expected to price during the week of Sept. 25, according to Nasdaq.com.
Since its founding the company has accumulated a deficit of £26.6 million ($36 million). Net losses totaled £5.3 million in 2015, £6 million in 2016 and £4.4 million for the six months ended June 30. As of that date it had £15.9 million in cash and cash equivalents.
Sofinnova is a longtime biotech investor founded in 1974 in Paris; in 1984 it opened up shop in Silicon Valley. Sofinnova has about $2.2 billion under management.
In November 2015, AstraZeneca plc (AZN) agreed to pay $90 per share, or $2.7 billion, for ZS Pharma, a company focused on developing treatments for hyperkalemia, a serious condition of elevated potassium in the bloodstream typically associated with chronic kidney disease.
ZS, which was backed by Sofinnova and other venture investors, went public in June 2014 for $28.50 per share.
More Biotech and Pharma IPOs to Watch:
Avista Capital Partners LP-backed ear, nose and throat specialty pharma company OptiNose Inc. looks to list on Nasdaq in the coming weeks, though no date has been forecast.
The company filed its S-1 on Monday, revealing that it had about $47.5 million in licensing revenue for 2016, mainly through a partnership with privately held Avanir Pharmaceuticals Inc. to develop migraine medication.
The company’s lead product, however, is XHance, a nasal spray used to treat nasal polyps in patients above the age of 18. On Monday, the U.S. Food and Drug Administration approved the new drug application. According to the S-1, the U.S. healthcare system spends approximately $60 billion annually in “direct costs treating patients with chronic rhinosinusitis and its associated symptoms, including an estimated $5 billion on sinus surgeries.”
New York private equity firm Avista Capital invested about $48.5 million in OptiNose and moved its headquarters from Oslo to Yardley, Pa. The company is led by former Johnson & Johnson Inc. (JNJ) executive Peter Miller.
Jefferies, Piper Jaffray & Co., BMO Capital Markets and RBC Capital Markets are underwriters on the IPO.
Another biotech looking to raise money in the coming weeks is Deciphera Pharmaceuticals Inc., which has said it would look to sell 6.25 million shares for $15 to $17 per share. Deciphera plans to list on Nasdaq as DCPH, according to its S-1.
Deciphera is a clinical-stage biopharmaceutical company developing kinase inhibitor treatments for a variety of cancers. Deciphera was founded in 2003 and is focused on developing a kinase inhibitor drug candidate to treat GIST, or gastrointestinal stromal tumors, which occur in the digestive tract. It has yet to turn a profit and has no significant source of revenue.
The Waltham, Mass., company is backed by venture firms including New Leaf Venture Partners LLC, Brightstar Associates LLC, SV Health Investors LLC and Viking Global Investors LP. New Leaf is probably the most well-known household name, having invested in a number of healthcare companies including Alder Biopharmaceuticals Inc. (ALDR) , now traded on Nasdaq and seeking to bring migraine treatments to market.
JPMorgan Securities LLC, JMP Securities LLC and Nomura Securities International Inc. are underwriting Deciphera’s offering.
Midstream Assets En Vogue?
BP plc’s (BP) U.S. midstream unit, BP Pipelines (North America) Inc., will offer some of its assets up for public investment through a newly formed master limited partnership, BP Midstream Partners LP. The MLP expects to list on the New York Stock Exchange under the ticker symbol BPMP.
BP revealed in mid-July it was considering an initial public offering of some of its U.S. assets as it continues to build its midstream business.
Following the BP Midstream Partners IPO, BP Pipelines will indirectly own the MLP’s general partner, a majority of its limited partner interests and all of its incentive distribution rights.
An MLP is a tax-advantaged structure most often employed by midstream oil and gas companies. Other major energy companies have launched MLP IPOs in recent years, including Royal Dutch Shell plc (RDS.A) , which raised nearly $1 billion in 2014.
BP Pipelines’ U.S. midstream infrastructure includes about 4,630 miles of crude oil, refined products, natural gas and diluent pipeline systems that transport about 2.1 million barrels of oil equivalent per day to refineries, refined products terminals, connecting pipelines and natural gas processing plants.
Following on BP’s heels were Oasis Midstream Partners and Howard Midstream Partners LP. Oasis said Wednesday it had priced 7.5 million shares at $17, below the $19 to $21 range. Notably, TheStreet’s sister publication The Deal reported in September 2016 that upstream oil and gas company Oasis Petroleum Inc. (OAS) was likely to sell or spin off its midstream units in 2017.
Howard Midstream, initially backed by EnLink Midstream Partners LP (ENLK) and Quanta Services Inc. (PWR) and now controlled by a unit of Alberta Investment Management Corp. and Cayman Islands investment firm Alinda Capital Partners LLC, provided a $200 million placeholder in its filing.
Welcome to … Fatburger?
Fat Brands Inc., the parent of Fatburger Inc., is hoping a “mini” IPO will turn customers into investors and raise enough capital for it to expand its franchise business worldwide, as it adds two new brands to its belt.
On Sept. 6, the Los Angeles global franchising company, which runs casual-dining chains Fatburger, Buffalo’s Cafe and Buffalo’s Express, applied, under Securities and Exchange Commission Regulation A, to list up to 2 million shares priced at $12 each on Nasdaq under ticker symbol FAT. Fat Brands, seeking to raise $24 million, will use the funds to further expand, through franchisees, its portfolio of brands worldwide.
Reg A allows the sale of IPO shares to individual investors, not just institutions. Along with its mini IPO, Fat Brands announced that it would complete the acquisition of Homestyle Dining LLC, the parent of Ponderosa Steakhouse and Bonanza Steakhouse, for $10.5 million. Across the Ponderosa and Bonanza brands, Fat Brands will gain 120 locations open and under development.
Fat Brands bought Southwestern-style casual dining chain Buffalo’s Cafe, known for its chicken wings, in 2011, and created a fast-casual version in 2012, Buffalo’s Express. Along with calorie-laden burger joint chain Fatburger, touted as the “Last Great Hamburger Stand,” Fat Brands already operates 200 locations open and under development in 18 countries, with plans to expand to 32.
The food industry has seen quite a shakeup recently, with the rise of in-home delivery services such as GrubHub Inc. (GRUB) as well as newer fast-casual restaurants such as Shake Shack Inc. SHAK continuing to take market share from the likes of Chili’s (owned by Brinker International Inc. (EAT) ) and Applebees International Inc. (owned by DineEquity Inc. (DIN) .)
Fat Burger CEO Andy Wiederhorn recently sat down with TheStreet to explain the rationale behind the IPO:
“The creation of Fat Brands has entered into the next step of our business plan of becoming a global franchise company with multiple brands. We bought the Fatburger brand almost 15 years ago with 40 restaurants just in California and Nevada, and we grew it to now have almost 200 restaurants and another 300 in our development pipeline. We felt it was time to create a multibrand holding company.”